Intrommune Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $3.49M

  • Investors
  • 6

Intrommune Therapeutics General Information

Description

Operator of a biotechnology company intended to develop a new and simple treatment for food allergies. The company's oral mucosal immunotherapy offers an easy and safe way to retrain the immune system to reduce the risk of exposure to foods, enabling patients and their families to use a formulated and fully functional toothpaste to incorporate and stabilize allergenic proteins.

Contact Information

Website
www.intrommune.com
Formerly Known As
Zenii
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Corporate Office
  • 20 West 125th Street Apartment 1
  • New York, NY 10027
  • United States
+1 (646)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Trenton Acquisition
Vertical(s)
Life Sciences
Corporate Office
  • 20 West 125th Street Apartment 1
  • New York, NY 10027
  • United States
+1 (646)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Intrommune Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 22-Jan-2024 $3.49M Completed Clinical Trials - Phase 2
4. Later Stage VC (Series B) 08-Feb-2022 Cancelled Clinical Trials - Phase 1
3. Later Stage VC (Series A) 01-Dec-2021 Completed Clinical Trials - Phase 1
2. Equity Crowdfunding 29-Jun-2018 $155K $155K Completed Pre-Clinical Trials
1. Merger/Acquisition 11-Sep-2017 Completed Pre-Clinical Trials
To view Intrommune Therapeutics’s complete valuation and funding history, request access »

Intrommune Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to develop a new and simple treatment for food allergies. The company's ora
Drug Discovery
New York, NY
15 As of 2022

Menlo Park, CA
 

Chatillon, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Intrommune Therapeutics Competitors (2)

One of Intrommune Therapeutics’s 2 competitors is Alladapt Immunotherapeutics, a Formerly VC-backed company based in Menlo Park, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alladapt Immunotherapeutics Formerly VC-backed Menlo Park, CA
DBV Technologies Formerly VC-backed Chatillon, France
You’re viewing 2 of 2 competitors. Get the full list »

Intrommune Therapeutics Patents

  • 3

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 2

    Pending

  • Expiring in next 12 mo

Intrommune Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024358743-A1 Methods of inducing tolerance and reducing adverse reactions to one or more food allergens Pending 10-Oct-2023
EP-4791428-A1 Methods of inducing tolerance and reducing adverse reactions to one or more food allergens Pending 10-Oct-2023
WO-2025080707-A1 Methods of inducing tolerance and reducing adverse reactions to one or more food allergens Inactive 10-Oct-2023 A61K39/35

Intrommune Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Intrommune Therapeutics FAQs

  • When was Intrommune Therapeutics founded?

    Intrommune Therapeutics was founded in 2015.

  • Where is Intrommune Therapeutics headquartered?

    Intrommune Therapeutics is headquartered in New York, NY.

  • What is the size of Intrommune Therapeutics?

    Intrommune Therapeutics has 15 total employees.

  • What industry is Intrommune Therapeutics in?

    Intrommune Therapeutics’s primary industry is Drug Discovery.

  • Is Intrommune Therapeutics a private or public company?

    Intrommune Therapeutics is a Private company.

  • What is Intrommune Therapeutics’s current revenue?

    The current revenue for Intrommune Therapeutics is .

  • How much funding has Intrommune Therapeutics raised over time?

    Intrommune Therapeutics has raised $9.6M.

  • Who are Intrommune Therapeutics’s competitors?

    Alladapt Immunotherapeutics and DBV Technologies are competitors of Intrommune Therapeutics.

  • When was Intrommune Therapeutics acquired?

    Intrommune Therapeutics was acquired on 22-Jan-2024.

  • Who acquired Intrommune Therapeutics?

    Intrommune Therapeutics was acquired by Trenton Acquisition.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process